An A3 Executive Reference (2 pages)

Japan rewards programs that are sequenced, evidenced, and locally socialized. To reduce calendar friction for senior teams, I’ve assembled a two-page, A3 reference that brings the decisive entry points onto one sheet with English-language URLs and brief cues that align with how work actually gets done here in Japan.

Curated Inside Without Clutter

• Regulation & pricing: PMDA scientific advice and pathways, MHLW policy touchpoints, Chuikyo reimbursement logic.

• Non-dilutive capital: AMED, JST/JSPS/NEDO—the programs that signal commitment and underwrite local proof.

• Clinical credibility: the six National Centers plus NHO for early-phase and pragmatic implementation data.

• Execution fabric: LINK-J, Shonan iPark, GTB, KBiCK for convening and pilots; JPWA/JAPTA for import & distribution realities.

• Standards & science: PMRJ/JP alignment, PSJ/JCA for normalization with clinicians and peers.

How to use it

Treat it as a routing aid: advocate → co-fund → consult → generate local evidence → normalize and scale. Each node is a doorway, not a detour; the sheet keeps those doors visible when decisions are time-bound.

Download the two-page A3 reference (PDF) and keep it on hand; for strategy and sequencing detail, see the full ecosystem guide: No registration needed and no unwanted follow-ups. Download our Japan Pharma Gateways (A3, 2 pages, PDF) here: Japan Pharma Ecosystem Contact List

If you need our commercial support, we stand ready to help you with strategies and execution. Book a meeting with us at: www.calendly.com/biosector or drop us an email at info@biosector.jp

Here’s our blog post that’s also downloadable as a PDF, diving a deeper into the Japanese Pharma Industry’s Ecosystem: Japan’s Pharma Ecosystem